Pulmatrix (NASDAQ:PULM – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.
Profitability
This table compares Pulmatrix and Silo Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulmatrix | N/A | -125.65% | -95.19% |
| Silo Pharma | -6,726.39% | -81.75% | -66.35% |
Institutional & Insider Ownership
11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 5.6% of Silo Pharma shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by insiders. Comparatively, 3.6% of Silo Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulmatrix | 1 | 0 | 0 | 0 | 1.00 |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
Risk and Volatility
Pulmatrix has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.
Earnings and Valuation
This table compares Pulmatrix and Silo Pharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulmatrix | $7.81 million | 0.66 | -$5.16 million | ($1.10) | -1.28 |
| Silo Pharma | $70,000.00 | 33.84 | -$4.23 million | ($4.36) | -0.34 |
Silo Pharma has lower revenue, but higher earnings than Pulmatrix. Pulmatrix is trading at a lower price-to-earnings ratio than Silo Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Silo Pharma beats Pulmatrix on 6 of the 11 factors compared between the two stocks.
About Pulmatrix
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
About Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
